JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY Journal
Overview
publication venue for
- Nasal allergen challenge (NAC): Practical aspects and applications from an EU/US perspective-a Work Group Report of the AAAAI Rhinitis, Rhinosinusitis and Ocular Allergy Committee. 151:1215-+. 2023
- Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count. 149:1711-+. 2022
-
Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial
. 149:1309-+. 2022 - Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study. 149:957-+. 2022
- EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management. 147:29-36. 2021
- Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. 146:595-605. 2020
- Omalizumab or dupilumab for chronic rhinosinusitis with nasal polyposis Reply 2021
- Pilot study of budesonide inhalant suspension irrigations for chronic eosinophilic sinusitis 2009
- Mepolizumab Induced Loss of Smell Improvement in Patients With Chronic Rhinosinusitis With Nasal Polyps From the SYNAPSE Study 2022
- Symptom Free Days In Patients With Severe Chronic Rhinosinusitis with Nasal Polyps Treated with Dupilumab 2022
- A Responder Analysis To Demonstrate Dupilumab Treatment Effect Across Objective and Patient-Reported Subjective Endpoints For Patients with Severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) 2021
- Mepolizumab Improves Health Related Quality of Life for Patients with Chronic Rhinosinusitis with Nasal Polyps: Data from the SYNAPSE study 2021
- Dupilumab Improves Sinus Opacification in All Sinuses in Patients With Severe Chronic Rhinosinusitis With Nasal Polyps (CRSwNP): Results From the SINUS-24 Phase 3 Study 2020
- Dupilumab Treatment Improves Sense of Smell in Patients With Chronic Rhinosinusitis With Nasal Polyps - Pooled Results From the SINUS-24 and SINUS-52 Phase 3 Trials 2020
- Omalizumab Improves Outcomes in Patients with Chronic Rhinosinusitis with Nasal Polyps Irrespective of Asthma Status 2020
- Omalizumab Improves Quality of Life in Patients with Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma 2020
- Efficacy and Safety of Dupilumab in Patients with Chronic Rhinosinusitis with Nasal Polyps: Results from the Randomized Phase 3 Sinus-24 Study 2019
- Efficacy and Safety of Dupilumab in Patients with Chronic Rhinosinusitis with Nasal Polyps: Results from the Randomized Phase 3 Sinus-24 Study 2019
- Time Course of Improvement in Individual Nasal Symptoms During a 2-Week Study of MP-AzeFlu in Patients with Seasonal Allergic Rhinitis (SAR) 2017
- Subpopulation of Lymphocytes for Chronic Sinusitis 2010
- Distinct immune profiles of chronic inflammatory, eosinophilic, aspirin insensitive, and fungal sinusitis 2008
Identity
International Standard Serial Number (ISSN)
- 0091-6749
Electronic International Standard Serial Number (EISSN)
- 1097-6825